All In Biotech

Drug Trial Radar · NCT02799095

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1

Last checked: Nov 19, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

243

Actual

Start

Sep 14, 2016

Primary completion

Mar 27, 2023

Study completion Aug 2, 2023

Sponsor

Lead sponsor
Mural Oncology, IncIndustry
Sponsor type
Industry
First posted
Jun 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To better understand the safety and tolerability of ALKS 4230 in humans

Conditions

  • Advanced Solid Tumors

Interventions

  • ALKS 4230Drug

    Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period

  • ALKS 4230 + pembrolizumabDrug

    IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)Time frame: Cycle 1 Day 1 through Cycle 2 Day 15 (Cycle 1 length = 14 days; Cycle 2 length= 21 days)
  2. Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of study drug until 30 days after last dose (up to 10 months for Part A; up to 41.3 months for Part B; up to 51.5 months for Part C)
  3. Parts A, B, and C: Number of Participants With TEAEs by Severity GradingTime frame: From first dose of study drug until 30 days after last dose (up to 10 months for Part A; up to 41.3 months for Part B; up to 51.5 months for Part C)
  4. Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1Time frame: From first dose of study drug up to 40.3 months for Part B and up to 50.5 months for Part C

Locations

31 sites in 7 countries. Site status is shown where the registry gives one.

  • Mural Oncology Investigational Site

    Denver, Colorado

  • Mural Oncology Investigational Site

    Port Saint Lucie, Florida

  • Mural Oncology Investigational Site

    Tampa, Florida

  • Mural Oncology Investigational Site

    Lexington, Kentucky

  • Mural Oncology Investigational Site

    Boston, Massachusetts

  • Mural Oncology Investigational Site

    Detroit, Michigan

  • Mural Oncology Investigational Site

    Buffalo, New York

  • Mural Oncology Investigational Site

    New York, New York

  • Mural Oncology Investigational Site

    Cleveland, Ohio

  • Mural Oncology Investigational Site

    Dallas, Texas

  • Mural Oncology Investigational Site

    Fairfax, Virginia

  • Mural Oncology Investigational Site

    Spokane, Washington

  • Mural Oncology Investgational Site

    Albury, New South Wales, Australia

  • Mural Oncology Investigational Site

    Waratah, New South Wales, Australia

  • Mural Oncology Investigational Site

    Brussels, MO, Belgium

  • Mural Oncology Investigational Site

    Kortrijk, West-Vlaanderen, Belgium

  • Mural Oncology Investigational Site

    Edmonton, Alberta, Canada

  • Mural Oncology Investigational Site

    Hamilton, Ontario, Canada

  • Alkermes Investigational Site

    Toronto, Ontario, Canada

  • Mural Oncology Investigational Site

    Montreal, Quebec, Canada

  • Mural Oncology Investigational Site

    Québec, Quebec, Canada

  • Mural Oncology Investigational Site

    Skorzewo, Poznan, Poland

  • Mural Oncology Investigational Site

    Daejeon, South Korea

  • Mural Oncology Investigational Site

    Seoul, South Korea

  • Mural Oncology Investigational Site

    Seoul, South Korea

  • Mural Oncology Investigational Site

    Barcelona, Spain

  • Mural Oncology Investigational Site

    Madrid, Spain

  • Mural Oncology Investigational Site

    Madrid, Spain

  • Mural Oncology Investigational Site

    Madrid, Spain

  • Mural Oncology Investigational Site

    Madrid, Spain

  • Mural Oncology Investigational Site

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.